top of page

Acoustically Triggered Nanorobotics Hold Promise for Cancer Treatment

Many incredible cancer-fighting drugs and treatments have been developed in the past few decades, and on paper, they seem like they hold the cure. Because of the way the human body is designed, however, the drugs have a difficult time actually reaching the cancerous site. Mechanical and Process Engineering Professor Daniel Ahmed at ETH Zurich in Switzerland, hopes to solve this challenge with nanorobots, tiny vehicles that can carry the drug right to the cancer.

The nanorobots aren’t what one might imagine when thinking about traditional robotics. They are made out of a biodegradable polymer, which are commonly referred to as microbubbles, that would burst and dissolve upon reaching their destination, releasing the drug. However, because they respond to the acoustic waves produced by ultrasound or a magnetic field they are considered robots and can be guided through the bloodstream using technology that is both noninvasive and familiar.

“The goal is to actually inject these robots into the body,” Ahmed said. “We want to deliver the drugs very locally so that patients don’t have any side effects.”

Side effects are a major concern in cancer treatment, typically because the medicine is injected into the bloodstream without any real goal but to kill cancer. The medicine often riddles the body causing hair loss, fatigue, nausea, and more. But, with Ahmed’s approach, the medicine would be delivered straight to the source, sparing the rest of the body from the drugs.

The self-assembled robots are slightly larger than red blood cells and can execute upstream motion against the bloodstream, as high as 1.2 mm per second. By studying various particle sizes and how they respond to ultrasound frequencies, he was able to pinpoint just the right diameter the nanorobots need to be in order to trap, or hold, them onto the outer wall of the blood vessel. Once trapped, he is able to push the bots along to the precise location of the cancer. Then he gives them a little shake and they release the drugs.

This technique could be especially useful for cancers like glioblastomas, which are typically found in the brain, but can also appear in the spine. Glioblastomas are large, rapidly growing tumors that leach fluid into surrounding tissues, otherwise known as interstitial fluid flow (IFF). IFFs cause intense pressure and there is no effective treatment option that can overcome it, making glioblastomas the deadliest form of cancer.

Early results on zebrafish embryo animal models are promising. But Ahmed explained that zebrafish embryos, although genetically similar to humans, have a very simple and soft structure. Therefore, the next phase of testing must be done on mice, which have a much more complex and rigid structure.

“Unfortunately, the vasculature of the mouse brain is super complicated,” he said. “Initially, we thought navigating our robots would be easy, but it's quite difficult. Frankly speaking, this is the hardest area to reach in the whole body of the mouse.”

He is interested in pushing the technology further. He envisions incorporating artificial intelligence so that the system can guide the nanorobots to the cancer site without manual instruction. One of the caveats of artificial intelligence, however, is that it requires big data.

“Getting a lot of data in the microrobotics field is currently difficult,” Ahmed said. “Of course you can rely on a simulation, but the problem then is reliability.”

Another challenge will be imaging. Ultrasound technology isn’t quite there yet when it comes to the speed and resolution the user would need to be able to perform this kind of procedure. The nanorobots are so small that it could be a challenge to get them to where they need to be. But Ahmed is hopeful that by the time his technology is ready, ultrasound technology will also be improved.

Ultimately, Ahmed wants to make sure he is using technology with which medical professionals are already familiar. This would make the procedure inexpensive and accessible.

“This kind of technology shouldn’t be reserved for the wealthy,” he said. “Everyone should benefit from it.”

Ahmed and his team will now move forward with mice studies and testing their technology in a range of environments in the body. He hopes to release more work this year and has an aggressive timeline to get to human trials in the next four to five years.



bottom of page